New hope for esophageal cancer: can immunotherapy keep the disease at bay?
NCT ID NCT06964568
Summary
This study is testing if adding a type of immunotherapy drug (a PD-1 inhibitor) as a long-term maintenance treatment after standard chemoradiation helps people with locally advanced esophageal cancer live longer without their cancer getting worse. It will involve 452 adults and is a Phase 3 trial, meaning it's a large-scale test to see if this approach is effective. The goal is to better control the disease and delay its progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.